Insmed reported $1.25B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Cytokinetics USD -737440000 471.03M Jun/2025
DBV Technologies USD 86.22M 83.35M Jun/2025
Dynavax Technologies USD 494.16M 36.78M Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
Insmed USD 1.25B 1.15B Jun/2025
Novartis USD 42.05B 1.99B Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025